Not exact matches
Vascepa has been approved for use
by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg / dL)
hypertriglyceridemia.
By blocking the expression of a certain gene in patients, University of Montreal researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their blood, even in various severe forms of
hypertriglyceridemia and regardless of the base values or the treatment the patient usually receives.
Hypertriglyceridemia, which can increase risk of both cardiovascular disease and pancreatitis, is often caused
by or exacerbated
by uncontrolled diabetes or obesity.
Sucrose is made up of glucose and fructose and it has been shown that diets very high in sucrose or fructose (~ 60 - 70 %
by energy) can induce
hypertriglyceridemia, insulin resistance and fatty liver.
Transgenic overexpression of APOC3 in mice also led to
hypertriglyceridemia that was likely due to defective lipolysis (20), but it should be noted that an excess of any apolipoprotein has a similar effect (26 — 29), probably
by shielding the core TG and preventing LPL access.
Our results support a model in which ApoC - III on TRLs contributes to
hypertriglyceridemia, primarily
by preventing TRL hepatic clearance via both LDLR and LRP1.
In conclusion, our genetic studies establish the fact that ApoC - III ASO reduces
hypertriglyceridemia in mice
by reducing plasma ApoC - III levels, which in turn enhances clearance of TRLs through LDLR family members.
~ Effect of high - amylose starch and oat bran on metabolic variables and bowel function in subjects with
hypertriglyceridemia (human study — full text) «We compared the effects of a diet in which 25 % of the carbohydrate was replaced
by high - amylose starch with those of a similar diet high in oat bran or low - amylose starch in 23 hypertriglyceridemic subjects who were overweight mostly because of abdominal adiposity.